Brokerages Anticipate G1 Therapeutics Inc (GTHX) to Announce -$0.58 Earnings Per Share
Equities analysts expect G1 Therapeutics Inc (NASDAQ:GTHX) to announce earnings per share (EPS) of ($0.58) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.53). G1 Therapeutics reported earnings of ($0.60) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.3%. The firm is scheduled to issue its next earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that G1 Therapeutics will report full-year earnings of ($2.49) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($2.43). For the next year, analysts expect that the business will post earnings of ($2.66) per share, with EPS estimates ranging from ($2.92) to ($2.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.08.
GTHX stock traded down $2.48 on Friday, reaching $32.45. 329,248 shares of the company’s stock were exchanged, compared to its average volume of 291,393. G1 Therapeutics has a twelve month low of $18.03 and a twelve month high of $69.57. The firm has a market capitalization of $1.28 billion, a PE ratio of -9.09 and a beta of 1.07.
In other G1 Therapeutics news, CFO Barclay A. Phillips sold 5,000 shares of the company’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $39.92, for a total value of $199,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $34.00, for a total value of $25,500.00. The disclosure for this sale can be found here. Insiders sold 60,363 shares of company stock worth $2,657,374 in the last three months. 15.92% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. FMR LLC boosted its stake in shares of G1 Therapeutics by 6.4% during the third quarter. FMR LLC now owns 5,216,663 shares of the company’s stock valued at $272,780,000 after acquiring an additional 313,931 shares during the last quarter. BlackRock Inc. boosted its stake in shares of G1 Therapeutics by 8.7% during the third quarter. BlackRock Inc. now owns 1,836,822 shares of the company’s stock valued at $96,048,000 after acquiring an additional 146,462 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of G1 Therapeutics by 76.3% during the third quarter. Vanguard Group Inc. now owns 1,717,733 shares of the company’s stock valued at $89,821,000 after acquiring an additional 743,596 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of G1 Therapeutics by 1,497.7% during the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after acquiring an additional 1,183,940 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of G1 Therapeutics by 19.9% during the third quarter. Capital World Investors now owns 1,215,000 shares of the company’s stock valued at $63,532,000 after acquiring an additional 202,000 shares during the last quarter. 71.02% of the stock is currently owned by institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Featured Article: Dollar Cost Averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.